342 related articles for article (PubMed ID: 17941033)
1. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma.
Hutterer GC; Patard JJ; Colombel M; Belldegrun AS; Pfister C; Guille F; Artibani W; Montorsi F; Pantuck AJ; Karakiewicz PI
Cancer; 2007 Dec; 110(11):2428-33. PubMed ID: 17941033
[TBL] [Abstract][Full Text] [Related]
2. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment.
Crépel M; Jeldres C; Perrotte P; Capitanio U; Isbarn H; Shariat SF; Liberman D; Sun M; Lughezzani G; Arjane P; Widmer H; Graefen M; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2010 Feb; 75(2):271-5. PubMed ID: 19962740
[TBL] [Abstract][Full Text] [Related]
3. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.
Leibovich BC; Blute M; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2004 Mar; 171(3):1066-70. PubMed ID: 14767272
[TBL] [Abstract][Full Text] [Related]
4. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma.
Margulis V; Tamboli P; Jacobsohn KM; Swanson DA; Wood CG
BJU Int; 2007 Dec; 100(6):1235-9. PubMed ID: 17979923
[TBL] [Abstract][Full Text] [Related]
5. Multiple ipsilateral renal tumors discovered at planned nephron sparing surgery: importance of tumor histology and risk of metachronous recurrence.
Blute M; Thibault GP; Leibovich BC; Cheville JC; Lohse CM; Zincke H
J Urol; 2003 Sep; 170(3):760-3. PubMed ID: 12913692
[TBL] [Abstract][Full Text] [Related]
6. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients.
Becker F; Siemer S; Humke U; Hack M; Ziegler M; Stöckle M
Eur Urol; 2006 Feb; 49(2):308-13. PubMed ID: 16359779
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.
Capitanio U; Zini L; Perrotte P; Shariat SF; Jeldres C; Arjane P; Pharand D; Widmer H; Péloquin F; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2008 Nov; 72(5):1090-5. PubMed ID: 18799207
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of multiple ipsilateral renal tumours found at the time of planned nephron-sparing surgery.
Krambeck A; Iwaszko M; Leibovich B; Cheville J; Frank I; Blute M
BJU Int; 2008 Jun; 101(11):1375-9. PubMed ID: 18454793
[TBL] [Abstract][Full Text] [Related]
9. Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes.
Pahernik S; Cudovic D; Roos F; Melchior SW; Thüroff JW
BJU Int; 2007 Jul; 100(1):26-9. PubMed ID: 17552949
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
Van Poppel H; Da Pozzo L; Albrecht W; Matveev V; Bono A; Borkowski A; Marechal JM; Klotz L; Skinner E; Keane T; Claessens I; Sylvester R; ; ; ;
Eur Urol; 2007 Jun; 51(6):1606-15. PubMed ID: 17140723
[TBL] [Abstract][Full Text] [Related]
11. Unclassified renal cell carcinoma: an analysis of 85 cases.
Karakiewicz PI; Hutterer GC; Trinh QD; Pantuck AJ; Klatte T; Lam JS; Guille F; de La Taille A; Novara G; Tostain J; Cindolo L; Ficarra V; Schips L; Zigeuner R; Mulders PF; Chautard D; Lechevallier E; Valeri A; Descotes JL; Lang H; Soulie M; Ferriere JM; Pfister C; Mejean A; Belldegrun AS; Patard JJ
BJU Int; 2007 Oct; 100(4):802-8. PubMed ID: 17822461
[TBL] [Abstract][Full Text] [Related]
12. Multiple ipsilateral renal tumors: retrospective analysis of surgical and oncological results of tumor enucleation vs radical nephrectomy.
Minervini A; Serni S; Giubilei G; Lanzi F; Vittori G; Lapini A; Carini M
Eur J Surg Oncol; 2009 May; 35(5):521-6. PubMed ID: 18640001
[TBL] [Abstract][Full Text] [Related]
13. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.
Zini L; Capitanio U; Perrotte P; Jeldres C; Shariat SF; Arjane P; Widmer H; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2009 Feb; 73(2):342-6. PubMed ID: 19041122
[TBL] [Abstract][Full Text] [Related]
14. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery.
Lerner SE; Hawkins CA; Blute ML; Grabner A; Wollan PC; Eickholt JT; Zincke H
J Urol; 1996 Jun; 155(6):1868-73. PubMed ID: 8618276
[TBL] [Abstract][Full Text] [Related]
15. [How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?].
Bigot P; Bernhard JC; Crepel M; Bensalah K; Azzouzi AR; de la Taille A; Salomon L; Tostain J; Ficarra V; Pantuck AJ; Belldegrun AS; Méjean A; Ferrière JM; Pfister C; Albouy B; Colombel M; Zini L; Villers A; Montorsi F; Shariat S; Rioux-Leclercq N; Patard JJ
Prog Urol; 2010 May; 20(5):350-5. PubMed ID: 20471579
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma.
Gratzke C; Seitz M; Bayrle F; Schlenker B; Bastian PJ; Haseke N; Bader M; Tilki D; Roosen A; Karl A; Reich O; Khoder WY; Wyler S; Stief CG; Staehler M; Bachmann A
BJU Int; 2009 Aug; 104(4):470-5. PubMed ID: 19239445
[TBL] [Abstract][Full Text] [Related]
17. Renal tumour surgery in elderly patients.
Roos FC; Pahernik S; Melchior SW; Thüroff JW
BJU Int; 2008 Sep; 102(6):680-3. PubMed ID: 18410435
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm.
Peycelon M; Hupertan V; Comperat E; Renard-Penna R; Vaessen C; Conort P; Bitker MO; Chartier-Kastler E; Richard F; Rouprêt M
J Urol; 2009 Jan; 181(1):35-41. PubMed ID: 19012929
[TBL] [Abstract][Full Text] [Related]
20. Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?
Crépel M; Isbarn H; Capitanio U; Liberman D; Jeldres C; Sun M; Shariat SF; Widmer H; Arjane P; Graefen M; Montorsi F; Patard JJ; Perrotte P; Karakiewicz PI
Urology; 2009 Oct; 74(4):842-5. PubMed ID: 19628262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
